“Clinical Outcomes for Metastatic Renal Cell Carcinoma (mRCC) Patients Ineligible for Front-line Clinical Trials”, jkcvhl, vol. 11, no. 3, pp. 51–58, Aug. 2024, doi: 10.15586/jkcvhl.v11i3.352.